[{"id":"dc418061-81ed-44f9-ba51-9700e1510d92","acronym":"","url":"https://clinicaltrials.gov/study/NCT06128551","created_at":"2023-11-13T16:14:48.821Z","updated_at":"2024-07-02T16:34:25.613Z","phase":"Phase 1","brief_title":"Study of RMC-6291 in Combination With RMC-6236 in Participants With Advanced KRAS G12C Mutant Solid Tumors","source_id_and_acronym":"NCT06128551","lead_sponsor":"Revolution Medicines, Inc.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e daraxonrasib (RMC-6236) • elironrasib (RMC-6291)"],"overall_status":"Recruiting","enrollment":" Enrollment 210","initiation":"Initiation: 11/14/2023","start_date":" 11/14/2023","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2024-06-17"},{"id":"77029856-029e-4b93-9d6a-51fc64859f73","acronym":"","url":"https://clinicaltrials.gov/study/NCT05462717","created_at":"2022-07-18T14:01:48.372Z","updated_at":"2024-07-02T16:35:08.511Z","phase":"Phase 1","brief_title":"Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors","source_id_and_acronym":"NCT05462717","lead_sponsor":"Revolution Medicines, Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS G12C","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS G12C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e elironrasib (RMC-6291)"],"overall_status":"Recruiting","enrollment":" Enrollment 222","initiation":"Initiation: 09/19/2022","start_date":" 09/19/2022","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-19"}]